NRXP•benzinga•
As Of December 31, 2024, NRx Pharmaceuticals Had Approximately $1.4M In Cash And Cash Equivalents And Completed Two Financings With Aggregate Gross Proceeds Of Approximately $8.5M That Is Expected To Provide Cash Runway Through At Least The End Of 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga